Pfizer and Kyowa Hakko Kirin have entered into an pharma alliance agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab.
PF-05082566 is an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137).
Mogamulizumab which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors.
Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer.
This study is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination.
This study is expected to begin in 2015 and the results will determine the future clinical development of the combination.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Pfizer
Report: Pancreatic Cancer Partnering 2007-2012
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity